Trial Profile
A Multicenter, Prospective, Adaptive, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effect of Interferon Lambda 1A, Fluvoxamina + Budesonida, Fluoxetina + Budesonida in Mild COVID-19 and High Risk of Complications
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 20 Nov 2023
Price :
$35
*
At a glance
- Drugs Budesonide (Primary) ; Fluoxetine (Primary) ; Fluvoxamine (Primary) ; Peginterferon beta-1a (Primary) ; Peginterferon lambda-1a (Primary) ; Paracetamol
- Indications COVID 2019 infections; Inflammation
- Focus Therapeutic Use
- Acronyms TOGETHER
- 10 Nov 2023 Planned End Date changed from 1 Nov 2023 to 1 Apr 2024.
- 10 Nov 2023 Planned primary completion date changed from 1 Oct 2023 to 1 Feb 2024.
- 18 Apr 2023 Results assessing (n=1482) the increase treatment effects of combination of fluvoxamine and inhaled budesonide in a highly vaccinated population, published in the Annals of Internal Medicine.